PEHALOVÁ, Lucie, Denisa KREJČÍ, Jana HALÁMKOVÁ, Lenka ŠMARDOVÁ, Lenka ŠNAJDROVÁ and Ladislav DUŠEK. Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients. Cancer Epidemiology. Oxford: Elsevier, 2021, vol. 72, June 2021, p. 1-8. ISSN 1877-7821. Available from: https://dx.doi.org/10.1016/j.canep.2021.101929.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
Authors PEHALOVÁ, Lucie (203 Czech Republic, guarantor, belonging to the institution), Denisa KREJČÍ (203 Czech Republic, belonging to the institution), Jana HALÁMKOVÁ (203 Czech Republic, belonging to the institution), Lenka ŠMARDOVÁ (203 Czech Republic, belonging to the institution), Lenka ŠNAJDROVÁ (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, belonging to the institution).
Edition Cancer Epidemiology, Oxford, Elsevier, 2021, 1877-7821.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.890
RIV identification code RIV/00216224:14110/21:00121472
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.canep.2021.101929
UT WoS 000652749700004
Keywords in English Haematological malignancies; Subsequent primary tumour; Time trends; Standardised incidence ratio; Survival
Tags 14110212, 14110522, 14110811, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/6/2021 13:17.
Abstract
Background Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies. Methods The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival. Results Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001). Conclusions Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.
PrintDisplayed: 9/7/2024 19:49